11 Most Oversold Penny Stocks to Buy Now
On August 20, Venu Krishna, the head of US equity strategy at Barclays, joined CNBC television to discuss the probable market response to the Federal Reserve's policy signals, particularly in light of...
Iovance Biotherapeutics Inc. (IOVA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | MHR Fund Management Mark Rachesky | 28,967,103 | $49,823,417 | +19% | 5.53% |
| 2. | Long Focus Capital Management John B. Helmers | 11,820,000 | $20,330,400 | +28% | 0.77% |
| 3. | Millennium Management Israel Englander | 9,330,223 | $16,047,984 | +5794% | 0.01% |
| 4. | Invenomic Capital Management Ali Motamed | 8,294,663 | $14,266,820 | +52% | 0.81% |
| 5. | Renaissance Technologies Jim Simons | 4,887,200 | $8,405,984 | +40% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.84 | 30,000 | $55,200.00 | 30,000 | 2025-06-05 | Filing | |
| $1.74 | 5,600 | $9,743.44 | 206,852 | 2025-05-23 | Filing | |
| $1.69 | 25,000 | $42,250.00 | 374,646 | 2025-05-14 | Filing | |
| $9.15 | 250,000 | $2,287,500.00 | 320,150 | 2024-02-20 | Filing | |
| $9.15 | 32,000 | $292,800.00 | 54,000 | 2024-02-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.06 | 50,000 | $503,000.00 | 7,500 | 2024-11-12 | Filing | |
| $8.71 | 20,500 | $178,612.40 | 100,000 | 2016-08-25 | Filing | |
| $9.10 | 33,500 | $304,799.75 | 120,500 | 2016-08-24 | Filing | |
| $9.11 | 54,000 | $491,740.20 | 100,000 | 2016-08-22 | Filing | |
| $7.13 | 16,500 | $117,645.00 | 154,000 | 2015-09-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 25,076,472 | $43,131,531 | 0% | |
| 2. | 23,236,812 | $39,967,317 | 0% | |
| 3. | 9,890,525 | $17,011,703 | 0% | |
| 4. | 6,450,933 | $11,095,606 | 0% | |
| 5. | 6,189,058 | $10,645,836 | 0% |
News See All
Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the most promising penny stocks under $5.
13 Most Promising Penny Stocks Under $5
On August 12, Jill Carey Hall, BofA Securities head of US small and mid-cap strategy, joined 'The Exchange' on CNBC to discuss the outlook for small caps, amidst their underperformance.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Iovance Biotherapeutics Second Quarter 2025 Financial Results Conference Call.
Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the penny stocks that will skyrocket. On July 15, Citizens JMP analyst Reni J. Benjamin reiterated a ‘Market Perform’ rating.
Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the best biotech penny stocks to buy right now. On July 15, Goldman Sachs downgraded Iovance Biotherapeutics, Inc.
14 Best Biotech Penny Stocks to Buy Right Now
He acknowledged that biotech has been a “super tough sector” either way, as there are hundreds of publicly traded stocks that do not add up to anything in aggregate.
10 Penny Stocks That Will Skyrocket
Valuations in the equity markets sit at historical highs, raising questions about future market performance.
Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 best healthcare penny stocks to buy according to analysts. Goldman Sachs reiterated its “Buy” rating on Iovance’s stock on June 3.
10 Best Healthcare Penny Stocks to Buy According to Analysts
According to the Centers for Medicare & Medicaid Services (CMS), the US healthcare sector accounted for approximately 17.6% of GDP in 2023.
Billionaire Hedge Funds
